Concepedia

John Proudfoot

JP

44

Publications

2.2K

Citations

25

H-Index

1984

Active since

Affiliations

Boehringer Ingelheim (United States)(Current)

Boehringer Ingelheim (Germany)

Boehringer Ingelheim (Japan)

Boehringer Ingelheim (France)

Stanford University

John Proudfoot is an author at Boehringer Ingelheim (United States) specializing in drug discovery, pharmacology, and medicine.

ORCID

Top concepts

Publications per year

1984–2017

44

Publications

44

Drugs, leads, and drug-likeness: an analysis of some recently launched drugs

John Proudfoot · Bioorganic & Medicinal Chemistry Letters · 2002 · 251 citations

, , +7

Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. Tricyclic pyridobenzo- and dipyridodiazepinones

Karl D. Hargrave, John Proudfoot, Karl Grozinger et al. · Journal of Medicinal Chemistry · 1991 · 208 citations · Full text

, , +16

A novel, dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site

Joseph C. Wu, Thomas C. Warren, Julian Adams et al. · Biochemistry · 1991 · 181 citations

Glossary of terms used in medicinal chemistry. Part II (IUPAC Recommendations 2013)

Derek R. Buckle, Paul Erhardt, C. Robin Ganellin et al. · Pure and Applied Chemistry · 2013 · 151 citations · Full text

, , +14

The evolution of synthetic oral drug properties

John Proudfoot · Bioorganic & Medicinal Chemistry Letters · 2005 · 124 citations

, , +5

Rows per page

1–5 of 44